Therapeutic Response
PD-L1 (TAP) >= 5% status confers therapeutic sensitivity to Cisplatin in combination with Paclitaxel and Tislelizumab in patients with Esophageal Squamous Cell Carcinoma.
Statements
| Source and description |
|---|
PD-L1 (TAP) >= 5% status confers therapeutic sensitivity to Cisplatin in combination with Paclitaxel and Tislelizumab in patients with Esophageal Squamous Cell Carcinoma.
| Source and description |
|---|